CLOV trades 17.8% below Wall Street's consensus target of $5.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CLOV achieves its forward estimates and maintains a stable P/E multiple of 83.4x. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 23, 2026, Clover Health Investments, Corp. (CLOV) has a Wall Street consensus price target of $5.50, based on estimates from 9 covering analysts. With the stock currently trading at $4.67, this represents a potential upside of +17.8%. The company has a market capitalization of $2.42B.
Analyst price targets range from a low of $5.00 to a high of $6.00, representing a 18% spread in expectations. The median target of $5.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 1 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 3 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, CLOV trades at a trailing P/E of -27.5x and forward P/E of 83.4x. Analysts expect EPS to grow +266.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HUMHumana Inc. | $44.7B | $371.93 | $418.53 | +12.5% | Hold | 40.6x | 44 |
 CVSCVS Health Corp. | $111.1B | $87.10 | $111.20 | +27.7% | Buy | 10.9x | 41 |
 ELVElevance Health Inc. | $87.3B | $402.43 | $444.06 | +10.3% | Buy | 14.8x | 38 |
 CNCCentene Corp. | $31.3B | $63.28 | $68.29 | +7.9% | Buy | 13.0x | 44 |
 MOHMolina Healthcare, Inc. | $10.0B | $191.19 | $205.45 | +7.5% | Buy | 36.5x | 39 |
 ALHCAlignment Healthcare, Inc. | $1.7B | $7.99 | $19.00 | +137.8% | Buy | 44.0x | 16 |
 OSCROscar Health, Inc. | $8.0B | $30.67 | $34.00 | +10.9% | Hold | 17.8x | 12 |
 BHVNBiohaven Ltd. | $2.2B | $14.85 | $20.00 | +34.7% | Buy | — | 25 |
 UNHUnitedHealth Group Incorporated | $338.7B | $372.95 | $473.89 | +27.1% | Buy | 18.8x | 52 |
 TDOCTeladoc Health, Inc. | $1.1B | $6.35 | $8.83 | +39.1% | Hold | — | 42 |
Quick answers to the most common questions about buying CLOV stock.
Clover Health Investments, Corp. (CLOV) has a consensus 12-month price target of $5.5, implying 17.8% upside from $4.67. The 9 analysts covering CLOV see moderate appreciation potential.
CLOV has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is leaning bearish, with 3 Sell/Strong Sell ratings. The consensus 12-month price target of $5.5 implies 17.8% upside from current levels.
At a forward P/E of 83.3929x, CLOV trades at a premium valuation. The consensus price target of $5.5 (17.8% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $6 for CLOV, while the most conservative target is $5. The consensus of $5.5 represents the median expectation. These targets typically reflect 12-month expectations.
CLOV is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 5 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CLOV stock forecast based on 9 Wall Street analysts shows a consensus price target of $5.5, with estimates ranging from $5 (bear case) to $6 (bull case). The median consensus rating is "Hold".
CLOV trades at a forward P/E ratio of 83.4x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on CLOV, with a "Hold" consensus rating and $5.5 price target (17.8% upside). 1 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CLOV analyst price targets range from $5 to $6, a 18% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.